We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Understanding, recognizing, and managing toxicities of targeted anticancer therapies.
- Authors
Dy, Grace K.; Adjei, Alex A.
- Abstract
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins are overexpressed or dysregulated in cancer cells compared with normal cells, it was assumed that their inhibitors will be narrowly targeted and relatively nontoxic. However, this hope has not been achieved. Current targeted agents exhibit the same frequency and severity of toxicities as traditional cytotoxic agents, with the main difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities of alopecia, myelosuppression, mucositis, nausea, and vomiting have been generally replaced by vascular, dermatologic, endocrine, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed. CA Cancer J Clin 2013;63:249-279. © 2013 American Cancer Society, Inc.
- Subjects
CANCER treatment; CANCER cells; CELL-mediated cytotoxicity; GENOMICS; CANCER chemotherapy; MOLECULAR biology
- Publication
CA: A Cancer Journal for Clinicians, 2013, Vol 63, Issue 4, p249
- ISSN
0007-9235
- Publication type
Article
- DOI
10.3322/caac.21184